Weekly Recap

Biogen Discontinues Aducanumab, CHMP Issues Negative Opinion on Ataluren, SRP-5051 Shines in MOMENTUM Study

ByNeurologyLive® Staff

February 3rd 2024

Neurology News Network for the week ending February 3, 2024. [WATCH TIME: 3 minutes]

Cell Therapy HLCM051 Falls Short in Stroke Study, Benefits of Light Therapy in Alzheimer, IPL344 Phase 2a Data Released

ByNeurologyLive® Staff

January 27th 2024

Neurology News Network for the week ending January 27, 2024. [WATCH TIME: 3 minutes]

ALS Agent PrimeC Moves to Phase 3, FDA Clears IND for AB126, APOE Carrier Status Impacts ARIA

ByNeurologyLive® Staff

January 20th 2024

Neurology News Network for the week ending January 21, 2024. [WATCH TIME: 3 minutes]

CBD Leads to Nonseizure Improvements, AbbVie Launches 24-Hour Levodopa Infusion in EU, CNM-Au8 Improves Visual Function and Cognition

ByMarco Meglio

January 13th 2024

Neurology News Network for the week ending January 13, 2024. [WATCH TIME: 4 minutes]

ALS Agent CNM-Au8 Reduces NfL, Positive CLEAR-MIND Results, Decreased Learning Abilities in Narcolepsy

ByNeurologyLive® Staff

January 6th 2024

Neurology News Network for the week ending January 6, 2023. [WATCH TIME: 3 minutes]

Trial of Ptau Therapy ACI-35.030 Launched, Positive Data on AMT-130 in Huntington Disease, CHMP Recommends EU Approval of Omeveloxolone

ByNeurologyLive® Staff

December 23rd 2023

Neurology News Network for the week ending December 23, 2023. [WATCH TIME: 4 minutes]

Topline Data on NE3017 Announced, Pitolisant Improves EDS in DM1, Nerivio Reduces Migraine Treatment Days

ByNeurologyLive® Staff

December 16th 2023

Neurology News Network for the week ending December 16, 2023. [WATCH TIME: 3 minutes]

Concomitant ASM Dosages With Stiripentol, FDA Pushes Givinostat Decision Back, Soticlestat Improves Caregiver Satisfaction

ByNeurologyLive® Staff

December 9th 2023

Neurology News Network for the week ending December 9, 2023. [WATCH TIME: 3 minutes]

Phase 2 Trial of Alzheimer Psychosis Initiated, FDA Declines to Lift Hold on ENTR-601-44, Levetiracetam and Clobazam With Safety Warnings

ByNeurologyLive® Staff

December 2nd 2023

Neurology News Network for the week ending December 1, 2023. [WATCH TIME: 4 minutes]

FDA Grants BrainStorm Meeting for NurOwn, Gene Therapy Study of AB-1005 Underway, VISION Trial to Test DBS Enhancement in PD

ByNeurologyLive® Staff

November 25th 2023

Neurology News Network for the week ending November 25, 2023. [WATCH TIME: 4 minutes

Valbenazine Shines in Open-Label Extension, FDA Grants Breakthrough Designation to NfL Test, Tocilizumab Effective in NMOSD

ByNeurologyLive® Staff

November 18th 2023

Neurology News Network for the week ending November 18, 2023. [WATCH TIME: 3 minutes]

FDA Clears Modius Sleep Device, NDA Accepted for SPN-830, Zilucoplan Improves Myasthenic Fatigue

ByNeurologyLive® Staff

November 11th 2023

Neurology News Network for the week ending November 11, 2023. [WATCH TIME: 3 minutes]

Migraine Preventive Prescription Trends, TAK-861 Phase 1 Study in Narcolepsy, Simufilam Not Associated With ARIA-E

ByNeurologyLive® Staff

November 4th 2023

Neurology News Network for the week ending November 4, 2023. [WATCH TIME: 3 minutes]

Solanezumab Fails A4 Alzheimer Study, FDA Lifts Hold on FREEDOM-DM1 Trial, CMS Announces Coverages of PET Amyloid-ß Imaging

ByNeurologyLive® Staff

October 21st 2023

Neurology News Network for the week ending October 21, 2023. [WATCH TIME: 3 minutes]

FDA Hands CRL to Patisiran, GBA1 Parkinson Trial Initiated, Levetiracetam Effective as First-Line Treatment in IGE Syndromes

ByNeurologyLive® Staff

October 14th 2023

Neurology News Network for the week ending October 14, 2023. [WATCH TIME: 3 minutes]

FDA Clears High Dose Cohort of CTI-1601, SOMNUM AI Device Approved, Intracranial Pressure Monitoring and TBI

ByNeurologyLive® Staff

October 7th 2023

Neurology News Network for the week ending October 7, 2023. [WATCH TIME: 3 minutes]

AdComm Committee Downvotes NurOwn, ADELY01 Cleared for Trials, Axsome Pushes Back SYMPHONY Trial

ByNeurologyLive® Staff

September 30th 2023

Neurology News Network for the week ending September 30, 2023. [WATCH TIME: 4 minutes]

FDA Approves AIRAscore, Pimavanserin Packing Label Updated, Blarcamesine Data Released

ByNeurologyLive® Staff

September 23rd 2023

Neurology News Network for the week ending September 23, 2023. [WATCH TIME: 3 minutes]

MS Treatments Linked With PML, Neflamapimod Effectiveness Based on P-Tau181 Levels, Nerivio Safe in Pregnant Women

ByNeurologyLive® Staff

September 16th 2023

Neurology News Network for the week ending September 16, 2023. [WATCH TIME: 3 minutes]

CNM-Au8 Improves Survival in ALS, New Parkinson Risk Factor Identified, Pamrevlumab Falls Short in Phase 3 Study

ByNeurologyLive® Staff

September 9th 2023

Neurology News Network for the week ending September 9, 2023. [WATCH TIME: 3 minutes]

Cell Therapy Bemdaneprocel Meets Primary Objective, Retinal Thickness in Parkinson Disease, TERIS Study Findings Published

ByNeurologyLive® Staff

September 2nd 2023

Neurology News Network for the week ending September 2, 2023. [WATCH TIME: 3 minutes]

DT-216 Reduces Frataxin Levels in FA, Valbenazine FDA-Approved for Huntington Chorea, EU Approves Atogepant as Migraine Preventive

ByNeurologyLive® Staff

August 26th 2023

Neurology News Network for the week ending August 26, 2023. [WATCH TIME: 3 minutes]

FDA Approves DaxibotulinumtoxinA for Cervical Dystonia, Genetic Parkinson Trial Announced, DBS Improves Poststroke Mobility

ByNeurologyLive® Staff

August 19th 2023

Neurology News Network for the week ending August 19, 2023. [WATCH TIME: 4 minutes]

Vyvgart Hytrulo Meets Primary End Point, Trial on Fibromyalgia-Type Long COVID Continues, Aspirin Increased Intracranial Bleeding in Elders

ByNeurologyLive® Staff

August 12th 2023

Neurology News Network for the week ending August 12, 2023. [WATCH TIME: 3 minutes]

MS Medications Added to WHO Essential List, Epigenome Therapy Shows Efficacy in AD, Phase 3 NEURO-TTransform Results Announced

ByNeurologyLive® Staff

August 5th 2023

Neurology News Network for the week ending August 5, 2023. [WATCH TIME: 4 minutes]

Positive Data on Dravet Therapy STK-001, FDA Clears Zoom 88 LDP Support, MS Diagnostic Guidelines Updated

ByNeurologyLive® Staff

July 29th 2023

Neurology News Network for the week ending July 29, 2023. [WATCH TIME: 4 minutes]

TRAILBLAZER-ALZ-2 Data of Donanemab Published, Risdiplam Effective in SMA up to 4 Years, Preclinical Alzheimer Study of Lecanemab Announced

ByNeurologyLive® Staff

July 22nd 2023

Neurology News Network for the week ending July 22, 2023. [WATCH TIME: 3 minutes]

Sleeping Pills and Increased Mortality, IPX203 Receives CRL, CT1812 Impacts Brain Function

ByNeurologyLive® Staff

July 8th 2023

Neurology News Network for the week ending July 8, 2023. [WATCH TIME: 3 minutes]

Gene Therapy AMT-130 in Huntington Disease, NDA Submitted for Troriluzole in Spinocerebellar Ataxia, FDA Clears Alzheimer Assays

ByNeurologyLive® Staff

July 1st 2023

Neurology News Network for the week ending July 1, 2023. [WATCH TIME: 3 minutes]

CNM-Au8 Reduces Neurofilament Light, Candesartan Benefits Headache, Ketamine Shows Potential in Migraine

ByNeurologyLive® Staff

June 24th 2023

Neurology News Network for the week ending June 24, 2023. [WATCH TIME: 3 minutes]

Weekly Recap

Biogen Discontinues Aducanumab, CHMP Issues Negative Opinion on Ataluren, SRP-5051 Shines in MOMENTUM Study

Cell Therapy HLCM051 Falls Short in Stroke Study, Benefits of Light Therapy in Alzheimer, IPL344 Phase 2a Data Released

ALS Agent PrimeC Moves to Phase 3, FDA Clears IND for AB126, APOE Carrier Status Impacts ARIA

CBD Leads to Nonseizure Improvements, AbbVie Launches 24-Hour Levodopa Infusion in EU, CNM-Au8 Improves Visual Function and Cognition

ALS Agent CNM-Au8 Reduces NfL, Positive CLEAR-MIND Results, Decreased Learning Abilities in Narcolepsy

Trial of Ptau Therapy ACI-35.030 Launched, Positive Data on AMT-130 in Huntington Disease, CHMP Recommends EU Approval of Omeveloxolone

Topline Data on NE3017 Announced, Pitolisant Improves EDS in DM1, Nerivio Reduces Migraine Treatment Days

Concomitant ASM Dosages With Stiripentol, FDA Pushes Givinostat Decision Back, Soticlestat Improves Caregiver Satisfaction

Phase 2 Trial of Alzheimer Psychosis Initiated, FDA Declines to Lift Hold on ENTR-601-44, Levetiracetam and Clobazam With Safety Warnings

FDA Grants BrainStorm Meeting for NurOwn, Gene Therapy Study of AB-1005 Underway, VISION Trial to Test DBS Enhancement in PD

Valbenazine Shines in Open-Label Extension, FDA Grants Breakthrough Designation to NfL Test, Tocilizumab Effective in NMOSD

FDA Clears Modius Sleep Device, NDA Accepted for SPN-830, Zilucoplan Improves Myasthenic Fatigue

Migraine Preventive Prescription Trends, TAK-861 Phase 1 Study in Narcolepsy, Simufilam Not Associated With ARIA-E

Solanezumab Fails A4 Alzheimer Study, FDA Lifts Hold on FREEDOM-DM1 Trial, CMS Announces Coverages of PET Amyloid-ß Imaging

FDA Hands CRL to Patisiran, GBA1 Parkinson Trial Initiated, Levetiracetam Effective as First-Line Treatment in IGE Syndromes

FDA Clears High Dose Cohort of CTI-1601, SOMNUM AI Device Approved, Intracranial Pressure Monitoring and TBI

AdComm Committee Downvotes NurOwn, ADELY01 Cleared for Trials, Axsome Pushes Back SYMPHONY Trial

FDA Approves AIRAscore, Pimavanserin Packing Label Updated, Blarcamesine Data Released

MS Treatments Linked With PML, Neflamapimod Effectiveness Based on P-Tau181 Levels, Nerivio Safe in Pregnant Women

CNM-Au8 Improves Survival in ALS, New Parkinson Risk Factor Identified, Pamrevlumab Falls Short in Phase 3 Study

Cell Therapy Bemdaneprocel Meets Primary Objective, Retinal Thickness in Parkinson Disease, TERIS Study Findings Published

DT-216 Reduces Frataxin Levels in FA, Valbenazine FDA-Approved for Huntington Chorea, EU Approves Atogepant as Migraine Preventive

FDA Approves DaxibotulinumtoxinA for Cervical Dystonia, Genetic Parkinson Trial Announced, DBS Improves Poststroke Mobility

Vyvgart Hytrulo Meets Primary End Point, Trial on Fibromyalgia-Type Long COVID Continues, Aspirin Increased Intracranial Bleeding in Elders

MS Medications Added to WHO Essential List, Epigenome Therapy Shows Efficacy in AD, Phase 3 NEURO-TTransform Results Announced

Positive Data on Dravet Therapy STK-001, FDA Clears Zoom 88 LDP Support, MS Diagnostic Guidelines Updated

TRAILBLAZER-ALZ-2 Data of Donanemab Published, Risdiplam Effective in SMA up to 4 Years, Preclinical Alzheimer Study of Lecanemab Announced

Sleeping Pills and Increased Mortality, IPX203 Receives CRL, CT1812 Impacts Brain Function

Gene Therapy AMT-130 in Huntington Disease, NDA Submitted for Troriluzole in Spinocerebellar Ataxia, FDA Clears Alzheimer Assays

CNM-Au8 Reduces Neurofilament Light, Candesartan Benefits Headache, Ketamine Shows Potential in Migraine

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Overviewing Promising Phase 1/2 Data of Gene Therapy ETX101 in Dravet Syndrome: Joseph Sullivan, MD

US Survey Reveals Underuse of Dravet Syndrome–Specific Antiseizure Medications in the Clinic

AES Poster Lays Insights Into EEG and MRI Biomarkers of MOGAD-Related Epilepsy

Dravet Syndrome Medication Stiripentol Effective in Real World Settings Across Various Patient Profiles

AES Presentations Highlight Zorevunersen as Disease-Modifying Treatment for Dravet Syndrome